Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled…
By N. Nishimoto, J. Hashimoto, N. Miyasaka, Kazuhiko Yamamoto, S. Kawai, T. Takeuchi, N. Murata, D. M. van der Heijde, T. Kishimoto. Annals of the Rheumatic Diseases, 2007
729 citations recorded by the source corpus.
Subfields: Rheumatology
View Paper: https://www.semanticscholar.org/paper/2ed93c3c947b37d5ae2e4f89a665f641958c974a
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Rheumatology
Citations in the corpus
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs (2010, positive): “It is noteworthy that some TNF inhibitors such as adalimumab and etanercept are licensed as mono-therapy on the basis of their effi cacy in clinical trials, but the data on their clinical superiority compared with MTX monotherapy are partly mixed.”
- IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. (2011, neutral): “patients [33].”
- IL‐1, IL‐18, and IL‐33 families of cytokines (2008, result): “However, like IL-1b, icIL-1Ra1 may be released from macrophages and endothelial cells through ATP stimulation of the P2X7 receptor (56, 57). icIL-1Ra1 may carry out unique functions inside cells including alteration of cytokine mRNA stability in epithelial cells (58), binding to the COP9 signalosome”
- Age and Age-Related Diseases: Role of Inflammation Triggers and Cytokines (2018, background): “Anti-IL-6R biologics, such as tociluzimab and anti-IL-6, such as sirukumab, strongly reduce disease activity and erosive progression (322, 323).”
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update (2010, positive): “Recent data suggest that monotherapy with tocilizumab is more effective than monotherapy with DMARDs such as MTX”